An observational study in Liver Fibrosis, sponsored by University Hospital, Grenoble. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.
Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 27th largest by planned enrollment of the 41 observational ones that give a count, is one of 5 that started in 2026, is one of 41 observational ones, reaches primary completion later than 16 of the 24 other live ones, and was the 87th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in France, Austria, Belgium and 9 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 10
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 205 across the 53 interventional studies, 227 across the 41 observational. Of the 63 that completed or were terminated, 11 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 3 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Liver Cirrhosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04530760University Hospital, LilleIntraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Liver Cirrhosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cirrhosis and hepatocellular carcinoma (HCC) are responsible for 25,000 deaths per year in France. The main causes are excessive alcohol consumption, metabolic steatosis, and hepatitis B and C. Fibrosis, classified from F0 (absence of fibrosis) to F4 (cirrhosis), is the sole determinant of liver-related mortality, particularly from stage F3. The incidence of metabolic steatosis is increasing, associated with a rise in mortality from chronic liver diseases (CLD). CLDs, often asymptomatic, are diagnosed late, reducing patient survival. Recommendations exist for the screening of hepatic fibrosis in at-risk patients (alcohol, diabetes, metabolic syndrome). This screening relies on calculating the FIB-4 score (calculated from widely prescribed variables: AST, ALT, platelets, age), followed by Fibroscan® (a non-invasive test for hepatic fibrosis) if FIB-4 > 1.3.
A Fibroscan® result \<8kPa excludes advanced fibrosis, while a result >9.6kPa suggests advanced fibrosis and ≥15kPa indicates cirrhosis. The appropriate care pathway includes a risk reduction program, a specialized consultation for patients with Fibroscan® ≥8kPa, and semi-annual screening for HCC in the case of cirrhosis. Indeed, it has been shown in a French cohort of patients with viral C cirrhosis that adherence to semi-annual screening is associated with better survival.
Eligible patients are primarily seen in primary care, and INCA has published a recommendation intended for general practitioners to improve the screening of fibrosis [13]. However, FIB-4 is poorly known among general practitioners [14], and access to Fibroscan® remains limited [15], hindering the implementation of the recommendations. Therefore, a care pathway has been established in the Grenoble area, initiated by Professor Costentin, allowing access to Fibroscan® for patients in primary care, starting from 2022 at the CHU. The objective is to evaluate the completion of the pathway, particularly the management of MCF risk factors and referral to specialized consultation for patients with Fibroscan® ≥8 kPa.
Patients from the Grenoble area underwent a Fibroscan® at CHU Grenoble Alpes or CPTS-SEG, upon request by a primary care practitioner, as part of hepatic fibrosis screening (FIB-4 >1.3, Fibroscan® ≥8kPa). Eligible patients will be contacted by a clinical research associate for a telephone questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study aims to describe and evaluate an existing care pathway, implemented within the framework of current clinical practice, without modifying the modalities of care or adding specific interventions. No additional procedures are imposed on participants, apart from data collection for evaluation purposes and telephone interviews.
Evaluation of managment of risk factors for significant liver fibrosis.
Proportion of patients with Fibroscan® ≥ 8kPa who received a specialized consultation in hepatogastroenterology in the year following the Fibroscan®
Time frame: Up to 30 months
Frequency of risk factors for liver fibrosis.
proprtion of patient with risk factors for liver fibrosis.
Time frame: Up to 30 months
Evaluation of managment of risk factors for liver fibrosis.
Proportion of patients who received appropriate management of identified risk factors.
Time frame: Up to 30 months
Evaluation of patients satisfaction after
Proportion of patients who satisfied with their care pathway evaluted with the 'patient' satisfaction and difficulties questionnaire .
Time frame: Up to 30 months
Evaluation of social determinals of health associated to the risks of advanced of liver fibrosis.
Estimation of the risks of advanced liver fibrosis according to the above definition associated with predefined variables of interest.
Time frame: up to 30 months
Evaluation of managment of risk factors for significant liver fibrosis in chu Grenoble Alpes patients .
Main judgment criterion estimated among patients screened at the university hospital.
Time frame: up to 30 months
Evaluation of the proportion of patients who had at least one specialized consultation within 12 months.
Proportion of patients who had at least one specialized consultation in 12 months.
Time frame: up to 30 months
Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 31 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →